Viatris Inc. vs Middle East Pharmaceutical Industries Company
A head-to-head of Viatris Inc. (VTRS) and Middle East Pharmaceutical Industries Company (4016) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | VTRS | 4016 |
|---|---|---|
| Market Cap | $20.14B | 2.06B SAR |
| P/E (TTM) | — | 12.46 |
| Forward P/E | 6.17 | 11.57 |
| P/S | 1.32 | 4.19 |
| P/B | 1.48 | 5.07 |
| EV/EBITDA | 7.62 | 9.59 |
| Dividend Yield | 2.56% | 2.39% |
| Profit Margin | -2.04% | 21.19% |
| Gross Margin | 35.06% | 62.29% |
| Operating Margin | 1.77% | 23.74% |
| Revenue Growth (YoY) | +8.07% | +33.65% |
| FCF Yield | 8.62% | 1.62% |
| Debt / Equity | 97.84 | 19.87 |
| Current Ratio | 1.60 | 2.85 |
Which is better: Viatris Inc. or Middle East Pharmaceutical Industries Company?
- ✓Larger by market cap: Viatris Inc.
- ✓Higher dividend yield: Viatris Inc.
- ✓More profitable (net margin): Middle East Pharmaceutical Industries Company
- ✓Faster revenue growth: Middle East Pharmaceutical Industries Company
- ✓Higher free-cash-flow yield: Viatris Inc.
Very close — each leads on 6 metrics.
There's no single "better" — it depends on your goal: income investors may prefer the higher yield, growth investors the faster grower, and value investors the cheaper one. See each stock's page for deeper detail. This is an automated read, not a recommendation.
Share:
Compare Viatris Inc. with others
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.